Detalles de la búsqueda
1.
Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patients.
J Transl Med
; 21(1): 174, 2023 03 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36872371
2.
Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer.
BMC Cancer
; 10: 85, 2010 Mar 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-20211022
3.
Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study.
Lung Cancer
; 147: 137-142, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32702570
4.
Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses.
J Thorac Oncol
; 15(2): 274-287, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31655296
5.
Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results.
Clin Lung Cancer
; 19(3): 213-220.e4, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29317191
6.
Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation-Positive Metastatic Non-Small-Cell Lung Cancer.
Clin Lung Cancer
; 18(1): 96-99, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27894601
Resultados
1 -
6
de 6
1
Próxima >
>>